Collaborative Agreements (Details) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified |
1 Months Ended | 6 Months Ended | 137 Months Ended | 6 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 0 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2012
|
Mar. 31, 2010
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2013
GSK
item
|
Oct. 28, 2010
GSK
Original Collaboration Agreement
|
Oct. 31, 2010
GSK
Original Collaboration Agreement
|
Jul. 17, 2012
GSK
Expanded Collaboration Agreement
item
|
Jul. 31, 2012
GSK
Expanded Collaboration Agreement
|
Jun. 30, 2013
GSK
Expanded Collaboration Agreement
|
Jul. 26, 2012
GSK
SPA
|
Jul. 17, 2012
GSK
SPA
|
Jul. 31, 2012
GSK
SPA
|
Jun. 30, 2013
GSK
SPA
|
Jun. 30, 2012
GSK
Clinical development objectives and the acceptance of regulatory filings milestone
|
Sep. 30, 2012
GSK
Clinical development objectives and the acceptance of regulatory filings milestone
Original Collaboration Agreement
|
Oct. 28, 2010
GSK
Clinical development objectives and the acceptance of regulatory filings milestone
Original Collaboration Agreement
|
Oct. 28, 2010
GSK
Market approvals for migalastat HCl milestone
Original Collaboration Agreement
|
Oct. 28, 2010
GSK
Achievement of certain sales thresholds milestone
Original Collaboration Agreement
|
Jul. 17, 2012
GSK
U.S. regulatory approval milestones for migalastat HCl monotherapy and migalastat HCl-ERT co-administration
|
Jul. 17, 2012
GSK
U.S. regulatory approval milestones for migalastat HCl monotherapy and migalastat HCl-ERT co-administration
Expanded Collaboration Agreement
|
Jul. 17, 2012
GSK
U.S. regulatory approval milestones for migalastat HCl monotherapy and migalastat HCl-ERT co-administration
Expanded Collaboration Agreement
Maximum
|
|
Collaborative Agreements | ||||||||||||||||||||||
Upfront payment received | $ 30,000,000 | |||||||||||||||||||||
Potential milestone payments receivable | 173,500,000 | 13,500,000 | 80,000,000 | 80,000,000 | 20,000,000 | |||||||||||||||||
Percentage of development costs funded by the entity | 40.00% | |||||||||||||||||||||
Stock issued from collaboration agreement (in shares) | 4.90 | 6.90 | 6.87 | 2.90 | 2.90 | |||||||||||||||||
Price per share of common stock issued as part of the license and collaboration agreement (in dollars per share) | $ 5.70 | $ 3.74 | $ 4.56 | $ 4.56 | $ 6.30 | $ 6.30 | ||||||||||||||||
Percentage of premium on average price per share of common stock issued as part of the license and collaboration agreement | 30.00% | |||||||||||||||||||||
Period preceding the closing date of the transaction over which average price per share of the company's stock is used | 60 days | |||||||||||||||||||||
Total value of the equity investment to the company | 62,000,000 | 62,057,000 | 193,441,000 | 31,000,000 | 31,000,000 | 18,600,000 | ||||||||||||||||
Ownership position in the company (as a percent) | 19.80% | 19.80% | ||||||||||||||||||||
Number of accounting units | 1 | |||||||||||||||||||||
Milestone revenue recognized | 3,500,000 | |||||||||||||||||||||
Number of exclusive licenses | 2 | |||||||||||||||||||||
Additional potential milestone payments receivable | 35,000,000 | |||||||||||||||||||||
Potential milestone payments received | 3,500,000 | |||||||||||||||||||||
Period of additional potential milestone payments receivable | 7 years | |||||||||||||||||||||
Percentage of development costs funded by the entity in 2012 | 25.00% | |||||||||||||||||||||
Percentage of development costs funded by the counterparty in 2012 | 75.00% | |||||||||||||||||||||
Percentage of development costs funded by the entity, thereafter | 40.00% | |||||||||||||||||||||
Percentage of development costs funded by the counterparty, thereafter | 60.00% | |||||||||||||||||||||
Percentage of development costs funded by the counterparty | 60.00% | |||||||||||||||||||||
Total purchase price (in dollars) | $ 18,600,000 | $ 18,600,000 | ||||||||||||||||||||
Lock-up period for common stock issued as a part of SPA | 6 months |